## Listing of Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously amended) A method for treating carcinoma, sarcoma, or dymphoma susceptible to treatment in a warm-blooded animal comprising administering to the warm-blooded animal a therapeutically effective amount of a compound of the following formula A-1:

$$\begin{array}{c} R \\ N \\ N \\ H \end{array}$$

A-1

wherein,

R is -CONR<sub>1</sub>R<sub>2</sub>, -OCOR<sub>1</sub> or -NHCOR<sub>1</sub>;

R<sub>1</sub> is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl; and

R2 is hydrogen or alkyl.

- (Previously amended) A method according to claim 1 wherein the compound is in the form of a
  pharmaceutically acceptable salt thereof.
- 3. (Original) A method according to claim 2 wherein said pharmaceutically acceptable salt is hydrochloride salt.

- 4. (Previously amended) A method according to claim 1 wherein the compound is in the form of a produce thereof.
- 5. (Cancelled)
- 6. (Original) A method according to claim 1 wherein R is -OCOR<sub>1</sub>.
- 7. (Original) A method according to claim 6 wherein R<sub>1</sub> is alkyl or substituted or unsubstituted phenyl.
- 8. (Original) A method according to claim 1 wherein said compound is micronized and is suitable for administering to said warm-blooded animal by injection.
- 9. (Original) A method according to claim 1 wherein said compound is administered in an amount of from 10 mg/kg body weight to 10,000 mg/kg body weight.
- 10. (Original) A method according to claim 1 wherein said compound is administered orally, enterically, intravenously, peritoneally, or by injection.
- 11. (Original) A method according to claim 1 wherein said compound is administered in a pharmaceutically acceptable carrier.
- 12. (Currently Amended) A method according to claim 1 wherein the method is for treating said cancer is a carcinoma.
- 13. (Cancelled)
- 14. (Previously amended) A method according to claim 12 wherein said careinoma is/melanoma.
- 15. (Previously amended) A method according to claim 12 wherein said carcinoma is colon cancer.
- 16. (Previously amended) A method according to claim 12 wherein said careinoma is breast cancer.

- 17. (Previously amended) A method according to claim 12 wherein said carcinoma is lung cancer;
- 18. (Previously amended) A method according to claim 12 wherein said carcinoma is pancreatic cancer.
- 19. (Previously amended) A method according to claim 12 wherein said carcinoma is ovarian cancer.
- 20. (Previously amended) A method according to claim 12 wherein said carcinoma is prostate cancer.
- 21. (Cancelled)
- 22. (Cancelled)
- 23. (Cancelled)
- 24. (Previously added) A method for treating leukemia susceptible to treatment in a warm-blooded animal comprising administering to the warm-blooded animal a therapeutically effective amount of a compound of the following formula A-1:

**A-**1

wherein,

R is OCOR; and

R<sub>1</sub> is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkyl, heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenyl, alkoxyalkyl, alkoxyalkyl,

A-162642\_1.DOC

poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl.